Global drug discovery Sygnature Discovery is a global CRO with 700+ scientists across Europe and North America, offering integrated drug discovery services from target identification to candidate nomination, creating recurring collaboration opportunities with pharma, biotech, and NFP organizations.

Strong track record With 60+ advanced candidates, 200+ patents filed, 200+ active projects, and 40+ pre-clinical compounds alongside 21 clinical compounds, the company demonstrates substantial value for customers seeking experienced, end-to-end discovery capabilities.

Strategic growth Recent expansions include a brand relaunch and new website, addition of ExpiCHO-S mammalian expression capability, and a major collaboration with STORM Therapeutics, signaling investments in platform depth and high-impact programs that can be leveraged in outreach.

Leadership and specialty Key hires like Head of In Vivo Pharmacology and specialized co-located teams in protein science, chemistry, computational chemistry, and pharmacology present opportunities to upsell integrated services, especially for oncology, immunology, neuroscience, and metabolic disease programs.

Commercial dynamics Reported revenue in the mid-range of multi-hundred-million scale for a CRO, combined with a high customer retention rate, indicates a stable base for expanding contracted R&D work, add-on services, and milestone-driven collaborations with current and prospective clients.